A5044886899- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pleural and Pulmonary Diseases
- Occupational and environmental lung diseases
- Colorectal Cancer Treatments and Studies
- Tracheal and airway disorders
- Multiple and Secondary Primary Cancers
- Palliative Care and End-of-Life Issues
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Pneumonia and Respiratory Infections
- Sarcoidosis and Beryllium Toxicity Research
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Lymphoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Cancer Research and Treatments
- Oral and Maxillofacial Pathology
- Health Systems, Economic Evaluations, Quality of Life
- Pneumothorax, Barotrauma, Emphysema
- Medical Imaging and Pathology Studies
Hôpital d'Instruction des Armées Sainte-Anne
2020-2025
Hôpital d'instruction des Armées Desgenettes
2011-2024
AlterSanté
2024
HIA du Val-de-Grâce à Paris
2024
Hôpital d'instruction des Armées Percy
2017-2022
Toulon Var Technologies (France)
2021
Université Paris-Est Créteil
2020
Université Sainte-Anne
2020
Institut Mondor de Recherche Biomédicale
2020
Centre Hospitalier Universitaire Henri-Mondor
2020
Among patients with resectable early-stage non–small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either alone. Download PDF of the Research Summary. We conducted randomized, double-blind, phase 3 trial to evaluate pembrolizumab in NSCLC. Participants stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned 1:1 ratio receive (200 mg) placebo once every weeks, each which was given...
IntroductionImmune-checkpoint inhibitor (ICI) efficacy in patients with NSCLC harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI against BRAF-, HER2-, MET-, and RET-NSCLC a real-world setting.MethodsIn this retrospective, multicenter ICI-treated MET- or RET-NSCLCs, we analyzed clinical characteristics outcomes: ICI-treatment duration, progression-free survival (PFS), objective response rate, duration of response, overall (OS).ResultsThere...
Abstract Introduction Preliminary reports indicated that smokers could be less susceptible to coronavirus SARS-CoV-2, which causes Covid-19. However, once infected an increased risk of severe disease is reported. We investigated the association between smoking and COVID-19 during outbreak on a naval vessel. Methods conducted cross-sectional, observational study 1769 sailors same navy aircraft carrier at sea exposed time SARS-CoV2 investigate link tobacco consumption Results Among 1688...
Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort.KBP-2020 was a prospective cohort that included all diagnosed with LC 2020, nonacademic public hospital France. Patient and tumour characteristics were described compared similarly designed cohorts 2000 2010.In 82 centers 8,999 LC. The proportion of women increased: 34·6% (3114/8999) to, 24·3% (1711/7051) 16·0% (904/5667) 2010 (p<0·0001). non-smokers higher...
9011 Background: Combination of anti-PD1 and CTLA4 have showed superiority to chemotherapy (CT) in advanced non–small cell lung cancer (NSCLC), but data for fit elderly or PS2 patients are scarce. Methods: eNErgy compared the combination nivolumab ipilimumab (N-I) a platinum doublet with NSCLC. Primary endpoint was overall survival (OS), secondary endpoints included progression-free (PFS), objective response rate (ORR), safety. Main inclusion criteria were: stage IV histologically proven...
First-line standard-of-care for unresectable, pleural mesothelioma (PM) changed with the phase 3 CheckMate 743 study results, showing that nivolumab plus ipilimumab (Nivo + Ipi) significantly extended overall survival (OS) versus platinum pemetrexed chemotherapy PM (median OS 18.1 14.1 months; hazard ratio: 0.74; p = 0.002). Efficacy and safety data in real-world (rw) settings are needed to confirm these results.
LBA100 Background: In patients (pts) with NSCLC, pembrolizumab (pembro) has shown efficacy as monotherapy in the adjuvant (adj) and advanced settings combination chemotherapy(chemo) metastatic disease. KEYNOTE-671 (NCT03425643), evaluated addition of pembro to platinum-based chemo neoadjuvant therapy followed by resection vs placebo adj early stage NSCLC. Methods: Eligible pts II, IIIA, or IIIB (N2) resectable NSCLC per AJCC v8 ECOG PS 0-1 were randomized 1:1 4 cycles 200 mg + cisplatin...
LBA8507 Background: To date, no treatment is recommended in MPM pts progressing after 1 st -line pemetrexed-platinum doublet. Disease control rate (DCR) <30% with all drugs tested 2 nd setting. Preliminary results suggested possible activity of anti-PD-1 mAb /3 rd- line, opposed to single agent anti-CTLA-4 mAb. Therefore anti-PD1 efficacy deserves confirmation, and + combination value currently unknown MPM. Methods: In this multicenter randomized non comparative phase trial, eligible had...
In an open-label multicenter non-randomized non-comparative phase II study in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC), oncogenic addiction (EGFR mutation or ALK/ROS1 fusion), disease progression after tyrosine-kinase inhibitor and no prior chemotherapy (NCT04042558), atezolizumab, carboplatin, pemetrexed without bevacizumab showed some promising result. Beyond the clinical evaluation, we assessed safety patient-reported outcomes (PROs) to provide...
The FDG-PET (fluorine-18 fluorodeoxyglucose positron emission tomography) scan is used with increasing frequency to investigate pleural abnormalities and determine the possibility of neoplastic invasion. However, false-positive findings are not uncommon talc pleurodesis has been reported cause hypermetabolic thickenings up 5 years after procedure. We report cases 3 patients (2 whom had a history asbestos exposure) requiring for recurrent pneumothoraces between 1988 1990, who were...
8012 Background: Neoadjuvant pembrolizumab + cisplatin-based chemotherapy (neoadj pembro chemo), resection, and adjuvant (adj) (pembro arm; n=397) significantly improved EFS, OS, pCR, mPR had an expected safety profile versus neoadj placebo (pbo) chemo, adj pbo (pbo n=400) in patients (pts) with resectable stage II, IIIA, or IIIB (N2) NSCLC. We present prespecified pt-reported outcome (PRO) endpoints from KEYNOTE-671. Methods: Pts completed EORTC QLQ-C30 QLQ-LC13 questionnaires at baseline...
Immune-checkpoint inhibitor (ICI) efficacy in patients with non-small cell lung cancer (NSCLC) harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI against epidermal growth-factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1)-mutated NSCLC the real-world setting.In this retrospective, multicenter on adults ICI-treated EGFR-mutated or ALK- ROS1-translated NSCLCs, we analyzed clinical characteristics and outcomes:...